The purpose of this study was to determine the proportion of pancreatic adenocarcinomas and pancreatic NETs with GPC3 and CK19 expression in our Canadian population and to determine if we could find prognostic value in these markers, as was previously reported by Yao et al. [2]. The gene discussed is GPC3; the disease is pancreatic adenocarcinoma.